Mark A Wingertzahn
Overview
Explore the profile of Mark A Wingertzahn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Culpepper L, Wingertzahn M
Prim Care Companion CNS Disord
. 2016 Apr;
17(6).
PMID: 27057416
Objective: To investigate the level of evidence supporting the use of common over-the-counter (OTC) agents (diphenhydramine, doxylamine, melatonin, and valerian) for occasional disturbed sleep or insomnia. Data Sources: A systematic...
2.
Kay G, Schwartz H, Wingertzahn M, Jayawardena S, Rosenberg R
Hum Psychopharmacol
. 2016 Mar;
31(3):217-26.
PMID: 27018419
Objective: Next-day residual effects of a nighttime dose of gabapentin 250 mg were evaluated on simulated driving performance in healthy participants in a randomized, placebo-controlled, double-blind, multicenter, four-period crossover study...
3.
Dicpinigaitis P, Eccles R, Blaiss M, Wingertzahn M
Curr Med Res Opin
. 2015 Jun;
31(8):1519-25.
PMID: 26073933
Background: Although the common cold is among the most frequent ailments encountered in clinical practice, little is known about its impact on productivity, absenteeism, and daily life. Objective: The United...
4.
Meltzer E, Blaiss M, Naclerio R, Stoloff S, Derebery M, Nelson H, et al.
Allergy Asthma Proc
. 2012 Sep;
33 Suppl 1:S113-41.
PMID: 22981425
Allergic rhinitis (AR; also nasal allergies or "hay fever") is a chronic upper airway inflammatory disease that affects ∼60 million adults and children in the United States. The duration and...
5.
Ratner P, Wingertzahn M, Herzog R, Huang H, Desai S, Maier G, et al.
Pulm Pharmacol Ther
. 2011 Apr;
24(4):426-33.
PMID: 21501692
Ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) is currently in development for treatment of allergic rhinitis. This Phase I study evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of CIC-HFA in healthy subjects...
6.
Neffen H, Wingertzahn M
Allergy Asthma Proc
. 2010 Jun;
31 Suppl 1:S29-37.
PMID: 20557684
Intranasal corticosteroids (INCSs) are established as the first-line treatment of moderate to severe allergic rhinitis (AR) in both adults and children. Compared with other nasal allergy medications, INCSs are the...
7.
Nasal allergies in the Latin American population: results from the Allergies in Latin America survey
Neffen H, Mello Jr J, Sole D, Naspitz C, Dodero A, Garza H, et al.
Allergy Asthma Proc
. 2010 Jun;
31 Suppl 1:S9-27.
PMID: 20557683
Allergies in Latin America is the first cross-national survey that describes the symptoms, impact, and treatment of nasal allergies (NAs) in individuals >or=4 years old in Latin America (LA). In...
8.
Nave R, Herzog R, Laurent A, Wingertzahn M
Clin Ther
. 2010 Jan;
31(12):2988-99.
PMID: 20110036
Background: Ciclesonide, an intranasal corticosteroid, is administered as a prodrug and is converted to the active metabolite, desisobutyryl ciclesonide, in the upper and lower airways. Previous studies have assessed systemic...
9.
LaForce C, van Bavel J, Meltzer E, Wingertzahn M
Ann Allergy Asthma Immunol
. 2009 Sep;
103(2):166-73.
PMID: 19739431
Background: Aerosol-based corticosteroid nasal formulations may be preferred over current aqueous nasal sprays by some patients because they traditionally cause less pharyngeal and anterior nose runoff. Objective: To determine the...
10.
Meltzer E, Blaiss M, Derebery M, Mahr T, Gordon B, Sheth K, et al.
J Allergy Clin Immunol
. 2009 Jul;
124(3 Suppl):S43-70.
PMID: 19592081
Allergic rhinitis (AR), a chronic inflammatory disease of the upper airway, is one of the most common chronic diseases in the United States and is estimated to affect up to...